Genmab Announces Start Of Ofatumumab Phase III Head To Head Study In DLBCL

Genmab A/S announced today the initiation of a Phase III study of Arzerra (TM) ofatumumab plus chemotherapy versus rituximab plus chemotherapy to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).